ADD 13 1000



Food and Drug Administration Rockville MD 20857

Re: AQUEOUS ARYL FLUOROPHOSPHITE SUSPENSION®

Docket No. 97E-0292

The Honorable Q. Todd Dickinson
Deputy Assistant Commissioner for
Patent Policy and Projects
Office of the Assistant Commissioner for Patents
U.S. Patent and Trademark Office
Crystal Park Building 2, Suite 919
Washington, DC 20231

Dear Commissioner Dickinson:

This is in regard to the patent term extension application for U.S. Patent No. 4,867,907 filed by Albemarle Corporation under 35 U.S.C. § 156. The patent claims the food additive AQUEOUS ARYL FLUOROPHOSPHITE SUSPENSION® (2,2'-ethylidenebis(4,6-di-tertbutylpheny)fluorophosphonite), food additive petition FAP 1B4281.

In the August 4, 1998, issue of the <u>Federal Register</u> (63 Fed. Reg. 41580), the Food and Drug Administration published its determination of this product's regulatory review period, as required under 35 U.S.C. § 156(d)(2)(A). The notice provided that on or before February 1, 1999, 180 days after the publication of the determination, any interested person could file a petition with FDA under 35 U.S.C. § 156(d)(2)(B)(i) for a determination of whether the patent term extension applicant acted with due diligence during the regulatory review period.

The 180-day period for filing a due diligence petition pursuant to this notice has expired and FDA has received no such petition. Therefore, FDA considers the regulatory review period determination to be final.

Please let me know if we can provide further assistance.

Sincerely yours,

Ronald L. Wilson, Director Health Assessment Policy Staff

Office of Health Affairs

cc: Teresa Stanek Rea

Burns, Doane, Swecker & Mathis, LLP

P.O. Box 1404

Alexandria, VA 22313-1404

975-0292

LET3

## **DEPARTMENT OF HEALTH & HUMAN SERVICES**

Public Health Service Food and Drug Administration

5 Memorandum P1:31

Date:

APR 1 3 1999

From:

Brian J. Malkin, Associate Director for Patents and Hearings

Health Assessment Policy Staff (HFY-20)

Subject: Patent Term Restoration Application

for AQUEOUS ARYL FLUOROPHOSPHITE SUSPENSION®

To: Dockets Management (HFA-305)

Attached is a letter to the Patent Term Office for the above mentioned drug under the Docket Number 97E-0292 stating that this particular patent is eligible for regulatory review. The Patent Number is 4,867,907. Please place this recent correspondence in the appropriate file.

If you have any questions, please contact me at 827-6620. Thank you for your assistance.